Sameeh Salama has over 25 years drug discovery experience across several disciplines and has held several senior level scientific and business development positions in both drug discovery and contract research organizations. Dr. Salama was actively involved in dozens of licensing and partnership agreements, including the licensing of Fedora’s Beta-lactamase inhibitors to F. Hoffman La Roche in a US$750 million license deal. He is also an active member of the Multi-sectoral Federal, Provincial and Territorial Task Group on Antimicrobial Resistance.
Dr. Salama currently serves as Vice-President of two biotechnology-focused organizations: Fedora Pharmaceuticals Inc., a clinical-stage drug discovery company with special interest in development of new antibiotics targeting multi-drug resistant infections; and Brass Dome Ventures (BDV), a management and consultancy company focused on managing, investing and founding new health care and biotechnology companies. Prior to Fedora and BDV Dr. Salama was also the Vice President of business development at NAEJA Pharmaceutical Inc. in charge of matters related to NAEJA’s contract research business. Prior to his tenure at NAEJA, he was Director of Microbiology at SynPhar Laboratories Inc.
In his scientific capacity, Dr. Salama played a senior role in the discovery and development of several antibiotics including beta-lactams, beta-lactamase inhibitors, fluoroquinolones, azoles, polyenes, as well as several natural products. As a microbiologist, his involvement included structure-activity relationship studies, and design and assessment of in vitro and in vivo assays to evaluate new antibacterial and antifungal agents. Dr. Salama received his Ph.D. in Medical Microbiology from the University of Salford, UK. He also published over 50 original research articles and presentations at international congresses and has seven original patents in the anti-infective and anti-inflammatory disease areas.
Dr. Salama serves on the Board of Directors for BioAlberta, AREF, Arabian Muslim Association (observer), and is on the Government of Canada Antimicrobial Resistance (AMR) Research and Innovation Task Group, AMR Industry Advocacy Group, and the World Health Organization’s (WHO) Global Antibiotic Research and Development Partnership (GARDP) REVIVE council group.